Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Servier Guilty Of ‘Involuntary Manslaughter’ in Mediator Safety Affair

French Regulator Fined For Delays In Product's Suspension

Executive Summary

The long-running Mediator saga reached a conclusion of sorts on 29 March when fines and sentences were handed out to those involved in delaying the withdrawal of a fenfluramine derivative that is thought to have caused many thousands of serious cardiac side-effects.

You may also be interested in...



New Head Of French Regulator Prioritizes Patient Safety

Christelle Ratignier-Carbonneil played a key part in strengthening the rules on drug safety following the Mediator weight loss drug scandal.

Servier Denies Deceit As French Mediator Trial Begins

A trial has begun in France to investigate the roles of the French firm Servier and the former drug regulator AFSSAPS in the Mediator scandal, where an amphetamine-like drug was kept on the market despite mounting evidence of its cardiac side-effects.

French agency head answers questions on Mediator "manslaughter"

Dominique Maraninchi, director general of the French medicines agency ANSM, has appeared before judges to answer questions relating to the agency's role in the Mediator affair, the agency has confirmed. The judges are investigating whether negligence on the part of the agency contributed to "manslaughter and involuntary injury" caused by the Servier drug between 1995 and 2009.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC144094

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel